Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots ...

painkiller Doliprane, and Pharmaton dietary supplement – will separate in the fourth quarter of 2024 “at the earliest.” The business – which has been operating as a standalone business ...

Adding OTC Cialis to Opella’s portfolio would complement its existing portfolio of popular OTC brands such as antihistamine Allegra, non-opioid pain reliever Doliprane, stomach cramp reliever ...

Doliprane), Opella, which generated €1.271 billion in Q3. Due to legal, regulatory, operational costs, and more emphasis on R&D investments, Sanofi's FCF will likely be reduced in the near term.